Hypnosis-based digital therapeutics (DTx)

for mental & physical health conditions

$Xm ARR with best-in-class health outcomes

• XX% avg. improvement in symptom management
• ~$XXX reduction in avg. healthcare spend per user
• Three DTx programs live, with XX more in the pipeline
• XX% of growth driven by health professional referrals, up from X% a year ago
• $Xm spent to get to $Xm ARR
• X month payback on CAC

SUMMARY

Treating a chronic condition is expensive, painful and underserved by traditional pharma

Chronic conditions like irritable bowel syndrome, addiction, anxiety & depression affect hundreds of millions of people but are complex and difficult to manage with drugs.

Non-drug approaches can help but since they are traditionally delivered by human therapists they struggle to reach the broad accessibility of pharmaceuticals and are prone to inconsistencies & high searching costs.

Patients resort to:

• Expensive, inaccessible therapy
• Restrictive lifestyle changes
• Ineffective, symptom specific medication

PROBLEM

Millions of people suffering from painful and expensive conditions

We help patients self-manage their conditions with hypnosis-based digital therapeutics

SOLUTION

Hypnosis is a state of absorption that that makes unconscious processes more receptive to change, amplifying the effectiveness of therapies like cognitive behavioral therapy (CBT) [1, 2]

Hundreds of controlled studies have shown hypnosis-based therapy to be effective in improving many chronic health conditions with results that drugs have been unable to achieve:

• Manage irritable bowel syndrome (IBS) symptoms by 60% [3, 4, 5]
• Increase smoking cessation 3x better than nicotine replacement [6, 7]
• Improve chronic pain better than opioids [8, 9, 10]

By automating hypnosis-based therapies, we’re utilizing the very qualities that have made drugs so successful – efficient scalability, on-demand availability, and total consistency - without the side effects or billion dollar price tag.

Digital medicine for underserved health conditions

Starting with irritable bowel syndrome

Our first app, Nerva: hypnotherapy to manage IBS symptoms with best-in-class results [11, 12]

• Daily audio hypnotherapy sessions, written lessons and breathing exercises
• $79 (3 months) or $149 (12 months)
• XX% gross margins that increase at scale
• XX% of WAU are DAU
• X hypnotherapy sessions per month per active user
• 9300 reviews averaging 4.6 stars

SOLUTION

The best IBS therapy, in your pocket, for 10% the cost

>XX% of users dramatically improve their symptom management

Pragmatic clinical trials

• n = 100,000+
• XX% average reduction in physical symptoms
• XX% average reduction in psychological symptoms
• ~$XX reduction in healthcare costs per user in a 6-month period

OUTCOMES

Consumer-grade growth with pharma-grade clinical rigor

D2C drives our healthcare flywheel

We’ve profitably acquired >100,000 patients through

direct-to-consumer channels, instead of paying millions for study participants.

XXx

LTV:CAC

On track for Xx in 6 months

X month

Payback

XX%

Monthly churn

GROWTH ENGINE

XXx

LTV:CAC

Instant

Payback

XX%

Monthly churn

3 month

Annual

Fast feedback loops from real-world data improve efficacy and generates best-in-class real-world health & economic outcomes.

Clinician referrals drive X% of our growth, up from X% a year ago

GROWTH ENGINE

Doctors, dietitians and other clinicians refer our programs to their patients at an increasing rate.

Referrals are largely organic via word of mouth - we don’t pay for referrals.

We're ready to amplify this flywheel with direct marketing, content and B2B partnerships.

~X% of our growth will come from clinician referrals in 12 months time.

And we’re seeing organic traction with partners

Inbound partnership opportunities driven by outcomes and D2C traction

GROWTH ENGINE

Leading GI Association platform partnership

Virtual care clinics

Health insurance funds

Research presentations at leading GI conferences

Large distribution brands (pharma, cosmetics, supplements, etc)

Research partners

COMPETITION

Cheaper, more effective & more accessible than any alternative

Low FODMAP diet

Nerva

Prescription DTx

Clinical effectiveness

No known side effects

​

Drug & diet free

Available globally

Accessible on-demand

Cost

$$$

$

$$

70-80% see clinically meaningful changes

63% see clinically meaningful changes

71% see clinically meaningful changes

PLATFORM

We’ve learned how to replicate the DTx playbook with increasing efficiency

Menopause ($14bn TAM)

3 months to launch (Oct 2021)

20 people to build

XX% reduction in hot flashes

XX% DAU / WAU

Quit Smoking ($25bn TAM)

3 months to launch (August 2022)

3 people to build

$XXk MRR in Month 4

Xx ROAS in Month 4

Pipeline of 10+ multi-billion dollar opportunities

Ecosystem = long-term retention

PLATFORM

Smoking Cessation

Menopause

Anxiety & Depression

Chronic pain

Sleep

Indication

Irritable bowel syndrome

Obesity

TAM

$21b

$14b

$25b

$75b

$60b

$80b

$192b

Mindset Health: Digital therapeutics platform

We turn clinical research into scalable, consumer-friendly digital therapeutic apps:

1. Select condition
2. Build & launch
3. Run pragmatic clinical trials
4. Scale through partnerships

PLATFORM

Shared technical infrastructure

Shared content engine and customer acquisition

Shared brand building, research & regulatory

TEAM

Alex Naoumidis

Co-CEO, Co-Founder Ex-accountant with celiac

disease

​

Chris Naoumidis

Co-CEO, Co-founder Self-taught engineer with chronic back pain

Dan Borthwick

CTO

Founding engineer @ $400m exit

+ 25 strong world-class in-person team from:

Content & Research Partners

Who are we?

Dr Simone Peters

Leading IBS Researcher and Clinician

Dr Michael Yapko

Clinical psychologist and world-leading hypnosis expert

Dr Irving Kirsch

Associate Director of Placebo Studies at Harvard

Dr Gary Elkins

Neuroscientist & Director of Mind-Body Lab at Baylor

A digitally native ‘pharma’ company helping the billion people with access to a phone but not good healthcare.

VISION

We’re raising $Xm to scale to $XXm ARR

In the next 24 months, we will:

P&L Summa

Total Subscribers

ARR

Gross Margin

Headcount

SERIES A FUNDRAISE

Total

DTx products

Optimize DTx platform to increase LTV by 50% through new programs, personalization, and more

Launch 4 new DTx for Anxiety & Depression, Sleep, Chronic Pain & Obesity

Scale distribution by ramping existing channels, testing new channels and increasing organic

Conduct real-world and controlled research to build brand and grow health/economic efficacy

Expand HCP and payer partnerships through utilising D2C and health/economic efficacy

Thanks.